Fully human bispecific antibodies for cancer treatment
The pipeline of the LamKap Bio group comprises five different bispecific molecules currently being in discovery / preclinical development. Please click on the buttons for additional information about our molecules.
LamKap Bio alpha
Program
Targets
Discovery
Preclinical
Clinical
NILK-2301
CEA x CD3
Status:
IND/CTA enabling
Format:
κλ body
Indications:
Solid tumors
Additional info:
NILK-2301 is a bispecific antibody that drives T cell retargeting to tumor cells by pairing a high affinity arm targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) to an anti-CD3 arm of optimized low affinity. The Fc-domain of NILK-2301 has been modified to avoid FcγR-binding whilst maintaining neonatal Fc receptor (FcRn) engagement. The generation of the production cell line for clinical material started in Q3/2020. IND/CTA filing is foreseen for Q1/2023.
NILK-3301
CEA x CD28
Status:
Preclinical
Format:
κλ body
Indications:
Solid tumors
Additional info:
NILK-3301 is a bispecific antibody that provides a costimulatory signal to T cells via the co-engagement of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA). Importantly, CD28 engagement is monovalent and is restricted by CEA present on tumor cells. The Fc-domain of NILK-3301 has been modified to avoid FcγR-binding whilst maintaining neonatal Fc receptor (FcRn) engagement. NILK-3301 can be used to enhance anti-tumor efficacy driven by T cell retargeting bispecific antibodies or synergize with e.g., checkpoint inhibitors. It is currently in preclinical development. The generation of the production cell line for clinical material started in Q3/2022.
LamKap Bio beta
Program
Targets
Discovery
Preclinical
Clinical
NILK-2401
CEA x CD47
Status:
IND/CTA enabling
Format:
κλ body
Indications:
Solid tumors
Additional info:
NILK-2401 is a bispecific antibody that drives selective and effective CD47 blockade to tumor cells expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5 aka CEA) by pairing a high affinity anti-CEA targeting arm to an anti-CD47 arm of optimized low affinity. As such, CD47 blockade is selective to CEA-bearing cells, thus avoiding unwanted CD47 blockade on other cell types (e.g., red blood cells and platelets). Due to its selectivity, the molecule contains a fully competent IgG1 Fc-domain allowing antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) effector functions. The generation of the production cell line for clinical material started in Q3/2020. IND/CTA filing is foreseen for Q1/2023.
LamKap Bio gamma
Program
Targets
Discovery
Preclinical
Clinical
NILK-2501
GPC3 x CD3
Status:
Discovery/early preclinical
Format:
κλ body
Indications:
Solid tumors
Additional info:
NILK-2501 is a bispecific antibody that drives T cell retargeting to tumor cells by pairing a high affinity arm targeting glypican-3 (GPC3) to an anti-CD3 arm of optimized low affinity. The Fc-domain of NILK-2301 has been modified to avoid FcγR-binding whilst maintaining neonatal Fc receptor (FcRn) engagement. NILK-2501 is currently in discovery phase of development.
NILK-3801
GPC3 x CD28
Status:
Discovery/early preclinical
Format:
κλ body
Indications:
Solid tumors
Additional info:
NILK-3801 is a bispecific antibody that provides a costimulatory signal to T cells via the co-engagement of glypican-3 (GPC3). Importantly, CD28 engagement is monovalent and is restricted by GPC3 present on tumor cells. The Fc-domain of NILK-3301 has been modified to avoid FcγR-binding whilst maintaining neonatal Fc receptor (FcRn) engagement. NILK-3801 can be used to enhance anti-tumor efficacy driven by T cell retargeting bispecific antibodies or synergize e.g., with checkpoint inhibitors. It is currently in discovery phase of development.
